Lisa K. Jennings - Publications

Affiliations: 
Cell Biology and Biochemistry University of Tennessee Health Science Center, Memphis, TN, United States 
Area:
Cell Biology, Oncology

124 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Ramsey MT, Fabian TC, Shahan CP, Sharpe JP, Mabry SE, Weinberg JA, Croce MA, Jennings LK. A prospective study of platelet function in trauma patients. The Journal of Trauma and Acute Care Surgery. PMID 26895088 DOI: 10.1097/TA.0000000000001017  0.92
2016 Garner JM, Herr MJ, Hodges KB, Jennings LK. The utility of tetraspanin CD9 as a biomarker for metastatic clear cell renal cell carcinoma. Biochemical and Biophysical Research Communications. PMID 26855131 DOI: 10.1016/j.bbrc.2016.02.008  0.92
2015 Bhal V, Herr MJ, Dixon M, Akins S, Hord E, White MM, Seiffert D, Kotha J, Jennings LK. Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model. Thrombosis Research. PMID 26412559 DOI: 10.1016/j.thromres.2015.09.009  0.92
2015 Chen X, Huang Y, Yang G, Li J, Wang T, Schulz OH, Jennings LK. Polydopamine Integrated Nanomaterials and Their Biomedical Applications. Current Pharmaceutical Design. PMID 26323424  0.92
2015 Giri S, Jennings LK. The spectrum of thrombin in acute coronary syndromes. Thrombosis Research. 135: 782-7. PMID 25764910 DOI: 10.1016/j.thromres.2015.02.013  0.92
2015 Judge HM, Jennings LK, Moliterno DJ, Hord E, Ecob R, Tricoci P, Rorick T, Kotha J, Storey RF. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. Platelets. 26: 236-42. PMID 24750101 DOI: 10.3109/09537104.2014.902924  0.92
2014 Tricoci P, Lokhnygina Y, Huang Z, Van de Werf F, Cornel JH, Chen E, Wallentin L, Held C, Aylward PE, Moliterno DJ, Jennings LK, White HD, Armstrong PW, Harrington RA, Strony J, et al. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. American Heart Journal. 168: 869-77.e1. PMID 25458650 DOI: 10.1016/j.ahj.2014.09.002  0.92
2014 Herr MJ, Mabry SE, Jennings LK. Tetraspanin CD9 regulates cell contraction and actin arrangement via RhoA in human vascular smooth muscle cells. Plos One. 9: e106999. PMID 25184334 DOI: 10.1371/journal.pone.0106999  0.92
2014 Chen J, Wang J, Schwab LP, Park KT, Seagroves TN, Jennings LK, Miller DD, Li W. Benzimidazole analogs as potent hypoxia inducible factor inhibitors: synthesis, biological evaluation, and profiling drug-like properties. Anticancer Research. 34: 3891-904. PMID 25075010  0.92
2014 Herr MJ, Longhurst CM, Baker B, Homayouni R, Speich HE, Kotha J, Jennings LK. Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activity. Biochemical and Biophysical Research Communications. 447: 616-20. PMID 24747564 DOI: 10.1016/j.bbrc.2014.04.046  0.92
2014 Speich HE, Bhal V, Houser KH, Caughran AT, Lands LT, Houng AK, Bäckstrom J, Enerbäck M, Reed GL, Jennings LK. Signaling via P2Y12 may be critical for early stabilization of platelet aggregates. Journal of Cardiovascular Pharmacology. 63: 520-7. PMID 24477045 DOI: 10.1097/FJC.0000000000000076  0.92
2014 Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jennings LK, Tricoci P, White HD, Armstrong PW, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Leonardi S, Rorick T, Held C, et al. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). The American Journal of Cardiology. 113: 936-44. PMID 24444781 DOI: 10.1016/j.amjcard.2013.11.052  0.92
2014 Storey RF, Kotha J, Smyth SS, Moliterno DJ, Rorick TL, Moccetti T, Valgimigli M, Dery JP, Cornel JH, Thomas GS, Huber K, Harrington RA, Hord E, Judge HM, Chen E, ... ... Jennings LK, et al. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thrombosis and Haemostasis. 111: 883-91. PMID 24402559 DOI: 10.1160/TH13-07-0624  0.92
2013 Jennings LK, Kotha J. The Utility of Platelet and Coagulation Testing of Antithrombotics: Fusing Science with Patient Care. Drug Development Research. 74: 587-593. PMID 24489427 DOI: 10.1002/ddr.21119  0.92
2013 Herr MJ, Mabry SE, Jameson JF, Jennings LK. Pro-MMP-9 upregulation in HT1080 cells expressing CD9 is regulated by epidermal growth factor receptor. Biochemical and Biophysical Research Communications. 442: 99-104. PMID 24246676 DOI: 10.1016/j.bbrc.2013.11.021  0.92
2013 Herr MJ, Kotha J, Hagedorn N, Smith B, Jennings LK. Tetraspanin CD9 promotes the invasive phenotype of human fibrosarcoma cells via upregulation of matrix metalloproteinase-9. Plos One. 8: e67766. PMID 23840773 DOI: 10.1371/journal.pone.0067766  0.92
2013 Speich HE, Furman RR, Lands LT, Moodie GD, Jennings LK. Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability. Journal of Thrombosis and Thrombolysis. 36: 31-41. PMID 23073747 DOI: 10.1007/s11239-012-0814-7  0.92
2012 Mills RM, Berkowitz RD, Damaraju CV, Jennings LK, Wildgoose P. Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study. Thrombosis Research. 130: 709-15. PMID 22857800 DOI: 10.1016/j.thromres.2012.07.014  0.92
2012 Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, McClure MW, Stephens G, Kochman J, Jennings LK, Gurbel PA, Wójcik J, Dabrowski M, Saucedo JF, Stumpf J, Buerke M, et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circulation. Cardiovascular Interventions. 5: 347-56. PMID 22619259 DOI: 10.1161/CIRCINTERVENTIONS.111.965608  0.92
2012 McCanless JD, Jennings LK, Bumgardner JD, Cole JA, Haggard WO. Hematoma-inspired alginate/platelet releasate/CaPO4 composite: initiation of the inflammatory-mediated response associated with fracture repair in vitro and ex vivo injection delivery. Journal of Materials Science. Materials in Medicine. 23: 1971-81. PMID 22588505 DOI: 10.1007/s10856-012-4672-9  0.92
2012 Rowley JW, Finn AV, French PA, Jennings LK, Bluestein D, Gross PL, Freedman JE, Steinhubl SR, Zimmerman GA, Becker RC, Dauerman HL, Smyth SS. Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses. Circulation. Cardiovascular Interventions. 5: 296-304. PMID 22511738 DOI: 10.1161/CIRCINTERVENTIONS.111.965426  0.92
2012 McCanless JD, Jennings LK, Cole JA, Bumgardner JD, Haggard WO. Induction of the early inflammatory-mediated cellular responses of fracture healing in vitro using platelet releasate-containing alginate/CaPO4 biomaterials for early osteoarthritis prevention. Journal of Biomedical Materials Research. Part A. 100: 1107-14. PMID 22337563 DOI: 10.1002/jbm.a.34038  0.92
2012 Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. European Journal of Clinical Pharmacology. 68: 1049-56. PMID 22315147 DOI: 10.1007/s00228-012-1217-6  0.92
2012 Jennings LK, Michelson AD, Jacoski MV, Tyagi A, Grgurevich S, Li JS, Picolo Investigators. Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response. Platelets. 23: 430-8. PMID 22309046 DOI: 10.3109/09537104.2011.650244  0.92
2012 McCanless JD, Jennings LK, Cole JA, Bumgardner JD, Haggard WO. In vitro differentiation and biocompatibility of mesenchymal stem cells on a novel platelet releasate-containing injectable composite. Journal of Biomedical Materials Research. Part A. 100: 220-9. PMID 22042623 DOI: 10.1002/jbm.a.33256  0.92
2012 Kosoglou T, Reyderman L, Kasserra C, Jennings LK, Young S, Xuan F, Pei J, Maxwell SE, Schiller J, Meehan AG, Cutler DL. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. European Journal of Clinical Pharmacology. 68: 291-300. PMID 21969227 DOI: 10.1007/s00228-011-1127-z  0.92
2011 Richardson MM, Jennings LK, Zhang XA. Tetraspanins and tumor progression. Clinical & Experimental Metastasis. 28: 261-70. PMID 21184145 DOI: 10.1007/s10585-010-9365-5  0.92
2010 Pasquali SK, Yow E, Jennings LK, Li JS. Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease. Congenital Heart Disease. 5: 552-5. PMID 21106014 DOI: 10.1111/j.1747-0803.2010.00461.x  0.92
2010 Hudson JQ, McNeely EB, Green CA, Jennings LK. Assessment of eptifibatide clearance by hemodialysis using an in vitro system. Blood Purification. 30: 266-71. PMID 21071937 DOI: 10.1159/000320766  0.92
2010 Becker RC, Gibson CM, Jennings LK, Morrow DA. Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions. The American Journal of Cardiology. 106: S2-3. PMID 20920638 DOI: 10.1016/j.amjcard.2010.08.026  0.92
2010 Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. Journal of the American College of Cardiology. 56: 919-33. PMID 20828644 DOI: 10.1016/j.jacc.2010.04.047  0.92
2010 Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation. 121: 784-91. PMID 20124127 DOI: 10.1161/CIRCULATIONAHA.109.882746  0.92
2010 Chandler AB, Earhart AD, Speich HE, Kueter TJ, Hansen J, White MM, Jennings LK. Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients. Thrombosis Research. 125: 44-52. PMID 19487018 DOI: 10.1016/j.thromres.2009.04.017  0.92
2009 Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thrombosis and Haemostasis. 102: 248-57. PMID 19652875 DOI: 10.1160/TH09-03-0192  0.92
2009 Speich HE, Earhart AD, Hill SN, Cholera S, Kueter TJ, Smith JN, White MM, Jennings LK. Variability of platelet aggregate dispersal with glycoprotein IIb-IIIa antagonists eptifibatide and abciximab. Journal of Thrombosis and Haemostasis : Jth. 7: 983-91. PMID 19548907 DOI: 10.1111/j.1538-7836.2009.03432.x  0.92
2009 Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet (London, England). 373: 919-28. PMID 19286091 DOI: 10.1016/S0140-6736(09)60230-0  0.92
2009 Jennings LK. Variability in platelet response to the antiplatelet agents aspirin and clopidogrel: mechanisms, measurement, and clinical relevance. Critical Pathways in Cardiology. 8: 20-8. PMID 19258834 DOI: 10.1097/HPC.0b013e318194e45e  0.92
2009 Zhang F, Kotha J, Jennings LK, Zhang XA. Tetraspanins and vascular functions. Cardiovascular Research. 83: 7-15. PMID 19251723 DOI: 10.1093/cvr/cvp080  0.92
2009 Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. The American Journal of Cardiology. 103: 40A-51A. PMID 19166712 DOI: 10.1016/j.amjcard.2008.11.023  0.92
2009 Jennings LK. Role of platelets in atherothrombosis. The American Journal of Cardiology. 103: 4A-10A. PMID 19166707 DOI: 10.1016/j.amjcard.2008.11.017  0.92
2009 Kotha J, Zhang C, Longhurst CM, Lu Y, Jacobs J, Cheng Y, Jennings LK. Functional relevance of tetraspanin CD9 in vascular smooth muscle cell injury phenotypes: a novel target for the prevention of neointimal hyperplasia. Atherosclerosis. 203: 377-86. PMID 18799160 DOI: 10.1016/j.atherosclerosis.2008.07.036  0.92
2008 Speich HE, Grgurevich S, Kueter TJ, Earhart AD, Slack SM, Jennings LK. Platelets undergo phosphorylation of Syk at Y525/526 and Y352 in response to pathophysiological shear stress. American Journal of Physiology. Cell Physiology. 295: C1045-54. PMID 18715989 DOI: 10.1152/ajpcell.90644.2007  0.92
2008 Jennings LK, Saucedo JF. Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. Current Opinion in Cardiology. 23: 302-8. PMID 18520712 DOI: 10.1097/HCO.0b013e3283021ad9  0.92
2008 Kotha J, Longhurst C, Appling W, Jennings LK. Tetraspanin CD9 regulates beta 1 integrin activation and enhances cell motility to fibronectin via a PI-3 kinase-dependent pathway. Experimental Cell Research. 314: 1811-22. PMID 18358474 DOI: 10.1016/j.yexcr.2008.01.024  0.92
2008 Li JS, Yow E, Berezny KY, Bokesch PM, Takahashi M, Graham TP, Sanders SP, Sidi D, Bonnet D, Ewert P, Jennings LK, Michelson AD. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. Circulation. 117: 553-9. PMID 18195173 DOI: 10.1161/CIRCULATIONAHA.107.715821  0.92
2008 Li JS, Yow E, Berezny KY, Bokesch PM, Takahashi M, Graham TP, Sanders SP, Sidi D, Bonnet D, Ewert P, Jennings LK, Michelson AD. Response to letter regarding article, "dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the platelet inhibition in children on clopidogrel (picolo) trial" Circulation. 118: e121. DOI: 10.1161/CIRCULATIONAHA.108.785030  0.92
2007 Dyke CM, Jennings LK, Maier G, Andreou C, Daly R, Tamberella MR. Preoperative platelet inhibition with eptifibatide during coronary artery bypass grafting with cardiopulmonary bypass. Journal of Cardiovascular Pharmacology and Therapeutics. 12: 54-60. PMID 17495258 DOI: 10.1177/1074248406299068  0.92
2007 Jennings LK, White MM. Platelet aggregation Platelets. 495-507. DOI: 10.1016/B978-012369367-9/50788-6  0.92
2006 Gibson CM, Kirtane AJ, Morrow DA, Palabrica TM, Murphy SA, Stone PH, Scirica BM, Jennings LK, Herrmann HC, Cohen DJ, McCabe CH, Braunwald E. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30). American Heart Journal. 152: 756-61. PMID 16996854 DOI: 10.1016/j.ahj.2006.04.016  0.92
2006 Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, Cohen DJ, Fish P, McCabe CH, Braunwald E. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. Journal of the American College of Cardiology. 47: 2364-73. PMID 16781360 DOI: 10.1016/j.jacc.2005.12.077  0.92
2006 Yang J, Ji R, Cheng Y, Sun JZ, Jennings LK, Zhang C. L-arginine chlorination results in the formation of a nonselective nitric-oxide synthase inhibitor. The Journal of Pharmacology and Experimental Therapeutics. 318: 1044-9. PMID 16717106 DOI: 10.1124/jpet.106.104422  0.92
2006 Gibson CM, Karmpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, Ray KK, Herrmann HC, Lakkis N, Kovach R, French W, Blankenship J, Lui HH, Palabrica T, Jennings LK, et al. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. The American Journal of Cardiology. 97: 1473-7. PMID 16679086 DOI: 10.1016/j.amjcard.2005.12.037  0.92
2005 Jennings LK. Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes. Expert Opinion On Drug Metabolism & Toxicology. 1: 727-37. PMID 16863436 DOI: 10.1517/17425255.1.4.727  0.92
2005 Cagiannos C, Abul-Khoudoud OR, DeRijk W, Shell DH, Jennings LK, Tolley EA, Handorf CR, Fabian TC. Rapamycin-coated expanded polytetrafluoroethylene bypass grafts exhibit decreased anastomotic neointimal hyperplasia in a porcine model. Journal of Vascular Surgery. 42: 980-8. PMID 16275457 DOI: 10.1016/j.jvs.2005.06.018  0.92
2005 Liu J, Jackson CW, Gruppo RA, Jennings LK, Gartner TK. The beta3 subunit of the integrin alphaIIbbeta3 regulates alphaIIb-mediated outside-in signaling. Blood. 105: 4345-52. PMID 15701721 DOI: 10.1182/blood-2004-07-2718  0.92
2005 He B, Liu L, Cook GA, Grgurevich S, Jennings LK, Zhang XA. Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin alpha6-mediated cell adhesion. The Journal of Biological Chemistry. 280: 3346-54. PMID 15557282 DOI: 10.1074/jbc.M406680200  0.92
2004 White MM, Krishnan R, Kueter TJ, Jacoski MV, Jennings LK. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists. Journal of Thrombosis and Thrombolysis. 18: 163-9. PMID 15815877 DOI: 10.1007/s11239-005-0341-x  0.92
2004 Saucedo JF, Lui HK, Garza L, Guerra GJ, Jacoski MV, Jennings LK. Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study. Journal of Thrombosis and Thrombolysis. 18: 67-74. PMID 15789173 DOI: 10.1007/s11239-004-0203-y  0.92
2004 Zhang C, Yang J, Jennings LK. Leukocyte-derived myeloperoxidase amplifies high-glucose--induced endothelial dysfunction through interaction with high-glucose--stimulated, vascular non--leukocyte-derived reactive oxygen species. Diabetes. 53: 2950-9. PMID 15504976 DOI: 10.2337/diabetes.53.11.2950  0.92
2004 Gibson CM, Jennings LK, Murphy SA, Lorenz DP, Giugliano RP, Harrington RA, Cholera S, Krishnan R, Califf RM, Braunwald E. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation. 110: 679-84. PMID 15262838 DOI: 10.1161/01.CIR.0000137912.11655.F6  0.92
2004 Saucedo JF, Garza L, Wolford DC, Cook SL, Ramanathan KB, Matin Z, McGrew FA, Jacoski MV, Jennings LK. Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study). The American Journal of Cardiology. 93: 1279-82. PMID 15135704 DOI: 10.1016/j.amjcard.2004.02.014  0.92
2004 Zhang C, Yang J, Jennings LK. Attenuation of neointima formation through the inhibition of DNA repair enzyme PARP-1 in balloon-injured rat carotid artery. American Journal of Physiology. Heart and Circulatory Physiology. 287: H659-66. PMID 15044192 DOI: 10.1152/ajpheart.00162.2004  0.92
2003 Zhang C, Yang J, Jacobs JD, Jennings LK. Interaction of myeloperoxidase with vascular NAD(P)H oxidase-derived reactive oxygen species in vasculature: implications for vascular diseases. American Journal of Physiology. Heart and Circulatory Physiology. 285: H2563-72. PMID 14613914 DOI: 10.1152/ajpheart.00435.2003  0.92
2003 Grgurevich S, Krishnan R, White MM, Jennings LK. Role of in vitro cholesterol depletion in mediating human platelet aggregation. Journal of Thrombosis and Haemostasis : Jth. 1: 576-86. PMID 12871469 DOI: 10.1046/j.1538-7836.2003.00087.x  0.92
2003 Haga JH, Slack SM, Jennings LK. Comparison of shear stress-induced platelet microparticle formation and phosphatidylserine expression in presence of alphaIIbbeta3 antagonists. Journal of Cardiovascular Pharmacology. 41: 363-71. PMID 12605014 DOI: 10.1097/00005344-200303000-00004  0.92
2003 Bhanoori M, Yellaturu CR, Ghosh SK, Hassid A, Jennings LK, Rao GN. Thiol alkylation inhibits the mitogenic effects of platelet-derived growth factor and renders it proapoptotic via activation of STATs and p53 and induction of expression of caspase1 and p21(waf1/cip1). Oncogene. 22: 117-30. PMID 12527914 DOI: 10.1038/sj.onc.1206065  0.92
2002 Haga JH, Jennings LK, Slack SM. Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists. Annals of Biomedical Engineering. 30: 1262-72. PMID 12540202 DOI: 10.1114/1.1528613  0.92
2002 Cook GA, Longhurst CM, Grgurevich S, Cholera S, Crossno JT, Jennings LK. Identification of CD9 extracellular domains important in regulation of CHO cell adhesion to fibronectin and fibronectin pericellular matrix assembly. Blood. 100: 4502-11. PMID 12453879 DOI: 10.1182/blood.V100.13.4502  0.92
2002 Zhang C, Yang J, Feng J, Jennings LK. Short-term administration of basic fibroblast growth factor enhances coronary collateral development without exacerbating atherosclerosis and balloon injury-induced vasoproliferation in atherosclerotic rabbits with acute myocardial infarction. The Journal of Laboratory and Clinical Medicine. 140: 119-25. PMID 12228768 DOI: 10.1067/mlc.2002.126343  0.92
2002 Yellaturu CR, Ghosh SK, Rao RK, Jennings LK, Hassid A, Rao GN. A potential role for nuclear factor of activated T-cells in receptor tyrosine kinase and G-protein-coupled receptor agonist-induced cell proliferation. The Biochemical Journal. 368: 183-90. PMID 12188924 DOI: 10.1042/BJ20020347  0.92
2002 Longhurst CM, Jacobs JD, White MM, Crossno JT, Fitzgerald DA, Bao J, Fitzgerald TJ, Raghow R, Jennings LK. Chinese hamster ovary cell motility to fibronectin is modulated by the second extracellular loop of CD9. Identification of a putative fibronectin binding site. The Journal of Biological Chemistry. 277: 32445-52. PMID 12068019 DOI: 10.1074/jbc.M204420200  0.92
2002 Jennings LK, Jacoski MV, White MM. The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. Journal of Interventional Cardiology. 15: 45-60. PMID 12053684  0.92
2001 Tcheng JE, Talley JD, O'Shea JC, Gilchrist IC, Kleiman NS, Grines CL, Davidson CJ, Lincoff AM, Califf RM, Jennings LK, Kitt MM, Lorenz TJ. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (The PRIDE Study) American Journal of Cardiology. 88: 1097-1102. PMID 11703951 DOI: 10.1016/S0002-9149(01)02041-0  0.92
2001 Gilchrist IC, O'Shea JC, Kosoglou T, Jennings LK, Lorenz TJ, Kitt MM, Kleiman NS, Talley D, Aguirre F, Davidson C, Runyon J, Tcheng JE. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation. 104: 406-11. PMID 11468201  0.92
2001 Tardiff BE, Jennings LK, Harrington RA, Gretler D, Potthoff RF, Vorchheimer DA, Eisenberg PR, Lincoff AM, Labinaz M, Joseph DM, McDougal MF, Kleiman NS. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: Prospective analysis from PURSUIT Circulation. 104: 399-405. PMID 11468200  0.92
2001 Madan M, Berkowitz SD, Christie DJ, Jennings LK, Smit AC, Sigmon KN, Glazer S, Tcheng JE. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention American Heart Journal. 141: 226-233. PMID 11174336 DOI: 10.1067/mhj.2001.112489  0.92
2000 Jennings LK, Haga JH, Slack SM. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thrombosis and Haemostasis. 84: 1095-102. PMID 11154119  0.92
2000 Mondoro TH, White MM, Jennings LK. Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization. Blood. 96: 2487-95. PMID 11001901  0.92
2000 Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, Tamby JF, Jensen BK, Nicolas SB, Jennings LK, Wise RJ, Braunwald E. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. American Heart Journal. 140: 81-93. PMID 10874267 DOI: 10.1067/mhj.2000.107172  0.92
1999 Cook GA, Wilkinson DA, Crossno JT, Raghow R, Jennings LK. The tetraspanin CD9 influences the adhesion, spreading, and pericellular fibronectin matrix assembly of Chinese hamster ovary cells on human plasma fibronectin Experimental Cell Research. 251: 356-371. PMID 10471321 DOI: 10.1006/excr.1999.4596  0.92
1999 Longhurst CM, White MM, Wilkinson DA, Jennings LK. A CD9, alphaIIbbeta3, integrin-associated protein, and GPIb/V/IX complex on the surface of human platelets is influenced by alphaIIbbeta3 conformational states. European Journal of Biochemistry / Febs. 263: 104-11. PMID 10429193 DOI: 10.1046/j.1432-1327.1999.00467.x  0.92
1998 Jackson DE, White MM, Jennings LK, Newman PJ. A Ser162-->Leu mutation within glycoprotein (GP) IIIa (integrin beta3) results in an unstable alphaIIbbeta3 complex that retains partial function in a novel form of type II Glanzmann thrombasthenia. Thrombosis and Haemostasis. 80: 42-8. PMID 9684783  0.92
1998 Longhurst CM, Jennings LK. Integrin-mediated signal transduction Cellular and Molecular Life Sciences. 54: 514-526. PMID 9676571 DOI: 10.1007/s000180050180  0.92
1998 Jennings LK, White MM. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors. American Heart Journal. 135: S179-83. PMID 9588397  0.92
1997 Wall CD, Conley PB, Armendariz-Borunda J, Sudarshan C, Wagner JE, Raghow R, Jennings LK. Expression of alpha IIb beta 3 integrin (GPIIb-IIIa) in myeloid cell lines and normal CD34+/CD33+ bone marrow cells. Blood Cells, Molecules & Diseases. 23: 361-76. PMID 9398537 DOI: 10.1006/bcmd.1997.0153  0.92
1997 Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, Scarborough RM. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 96: 1488-94. PMID 9315536  0.92
1997 Brisson C, Azorsa DO, Jennings LK, Moog S, Cazenave JP, Lanza F. Co-localization of CD9 and GPIIb-IIIa (α(IIb) β3 integrin) on activated platelet pseudopods and α-granule membranes Histochemical Journal. 29: 153-165. PMID 9147072  0.92
1996 Mondoro TH, Wall CD, White MM, Jennings LK. Selective induction of a glycoprotein IIIa ligand-induced binding site by fibrinogen and von Willebrand factor. Blood. 88: 3824-30. PMID 8916946  0.92
1996 Jennings LK, Slack SM, Wall CD, Mondoro TH. Immunological comparisons of integrin α(IIIbβ3) (GPIIb-IIIa) expressed on platelets and human erythroleukemia cells: Evidence for cell specific differences Blood Cells, Molecules, and Diseases. 22: 23-35. PMID 8807083 DOI: 10.1006/bcmd.1996.0005  0.92
1996 White MM, Jennings LK, Siders L, White FL. Effect of heparin removal filter. American Journal of Clinical Pathology. 105: 372. PMID 8602622  0.92
1995 Jennings LK, White MM, Mandrell TD. Interspecies comparison of platelet aggregation, LIBS expression and clot retraction: observed differences in GPIIb-IIIa functional activity. Thrombosis and Haemostasis. 74: 1551-6. PMID 8772236  0.92
1995 Wall JE, Buijs-Wilts M, Arnold JT, Wang W, White MM, Jennings LK, Jackson CW. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. British Journal of Haematology. 89: 380-5. PMID 7873389  0.92
1994 Kouns WC, Steiner B, Kunicki TJ, Moog S, Jutzi J, Jennings LK, Cazenave JP, Lanza F. Activation of the fibrinogen binding site on platelets isolated from a patient with the Strasbourg I variant of Glanzmann's thrombasthenia Blood. 84: 1108-1115. PMID 8049427  0.92
1994 Jennings LK, Crossno JT, Fox CF, White MM, Green CA. Platelet p24/CD9, a member of the tetraspanin family of proteins. Annals of the New York Academy of Sciences. 714: 175-84. PMID 8017766 DOI: 10.1111/j.1749-6632.1994.tb12042.x  0.92
1994 Slack SM, Jennings LK, Turitto VT. Platelet size distribution measurements as indicators of shear stress-induced platelet aggregation Annals of Biomedical Engineering. 22: 653-659. PMID 7532923 DOI: 10.1007/BF02368290  0.92
1994 Heath TL, Wall CD, Jennings LK. A GP IIIa ligand-induced binding site antibody detects multiple GP IIb-IIIa conformations, and its binding is modulated by various ligands Annals of the New York Academy of Sciences. 714: 300-302. PMID 7517115 DOI: 10.1111/j.1749-6632.1994.tb12061.x  0.92
1993 Jennings LK, White MM, Sauer CM, Mauer AM, Robertson JT. Cocaine-induced platelet defects. Stroke; a Journal of Cerebral Circulation. 24: 1352-9. PMID 8362430  0.92
1992 White MM, Foust JT, Mauer AM, Robertson JT, Jennings LK. Assessment of lumiaggregometry for research and clinical laboratories. Thrombosis and Haemostasis. 67: 572-7. PMID 1519217  0.92
1992 White MM, Siders L, Jennings LK, White FL. The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia. Thrombosis and Haemostasis. 68: 88. PMID 1514180  0.92
1992 Kouns WC, Kirchhofer D, Hadváry P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor Blood. 80: 2539-2547. PMID 1384788  0.92
1992 White McC. M, Siders L, Jennings LK, White FL. The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia [2] Thrombosis and Haemostasis. 68: 90.  0.92
1991 Lanza F, Wolf D, Fox CF, Kieffer N, Seyer JM, Fried VA, Coughlin SR, Phillips DR, Jennings LK. cDNA cloning and expression of platelet p24/CD9: Evidence for a new family of multiple membrane-spanning proteins Journal of Biological Chemistry. 266: 10638-10645. PMID 2037603  0.92
1991 Jennings LK, Wang WC, Jackson CW, Fox CF, Bell A. Hemostasis in glanzmann’s thrombasthenia (GT): Gt platelets interfere with the aggregation of normal platelets Journal of Pediatric Hematology/Oncology. 13: 84-90. PMID 2029084  0.92
1991 Kouns WC, Jennings LK. Activation-independent exposure of the GPIIb-IIIa fibrinogen receptor Thrombosis Research. 63: 343-354. PMID 1957276 DOI: 10.1016/0049-3848(91)90137-L  0.92
1991 Kouns WC, Fox CF, Lamoreaux WJ, Coons LB, Jennings LK. The effect of glycoprotein IIb-IIIa receptor occupancy on the cytoskeleton of resting and activated platelets Journal of Biological Chemistry. 266: 13891-13900. PMID 1906886  0.92
1991 Rubinstein E, Kouns WC, Jennings LK, Boucheix C, Carroll RC. Interaction of two GPIIb/IIIa monoclonal antibodies with platelet Fc receptor (Fc gamma RII). British Journal of Haematology. 78: 80-6. PMID 1828363  0.92
1991 Kouns WC, Newman PJ, Puckett KJ, Miller AA, Wall CD, Fox CF, Seyer JM, Jennings LK. Further characterization of the loop structure of platelet glycoprotein IIIa: Partial Mapping of functionally significant glycoprotein IIIa epitopes Blood. 78: 3215-3223. PMID 1720699  0.92
1990 Jennings LK, Fox CF, Kouns WC, McKay CP, Ballou LR, Schultz HE. The activation of human platelets mediated by anti-human platelet p24/CD9 monoclonal antibodies. The Journal of Biological Chemistry. 265: 3815-22. PMID 2303480  0.92
1990 Kouns WC, Wall CD, White MM, Fox CF, Jennings LK. A conformation-dependent epitope of human platelet glycoprotein IIIa. The Journal of Biological Chemistry. 265: 20594-601. PMID 1700791  0.92
1989 Jackson CW, Jennings LK. Heterogeneity of fibrinogen receptor expression on platelets activated in normal plasma with ADP: Analysis by flow cytometry British Journal of Haematology. 72: 407-414. PMID 2765407  0.92
1989 Jennings LK, Dockter ME, Wall CD, Fox CF, Kennedy DM. Calcium mobilization in human platelets using indo-1 and flow cytometry Blood. 74: 2674-2680. PMID 2510834  0.92
1988 Jennings LK, Jackson CW. Heterogeneity of fibrinogen receptor expression on human platelets activated by ADP in native plasma Progress in Clinical and Biological Research. 283: 381-385. PMID 3211956  0.92
1988 Loftus JC, Plow EF, Jennings LK, Ginsberg MH. Alternative proteolytic processing of platelet membrane glycoprotein IIb Journal of Biological Chemistry. 263: 11025-11028. PMID 2457017  0.92
1986 Jennings LK, Ashmun RA, Wang WC, Dockter ME. Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann's thrombasthenia in whole blood by flow cytometry Blood. 68: 173-179. PMID 3719095  0.92
1986 Singer JA, Jennings LK, Jackson CW, Dockter ME, Morrison M, Walker WS. Erythrocyte homeostasis: Antibody-mediated recognition of the senescent state by macrophages Proceedings of the National Academy of Sciences of the United States of America. 83: 5498-5501. PMID 3016705 DOI: 10.1073/pnas.83.15.5498  0.92
1985 Jennings LK, Phillips DR, Walker WS. Monoclonal antibodies to human platelet glycoprotein IIbβ that initiate distinct platelet responses Blood. 65: 1112-1119. PMID 3158361  0.92
1985 Jennings LK, Brown LK, Dockter ME. Quantitation of protein 3 content of circulating erythrocytes at the single-cell level Blood. 65: 1256-1262. PMID 2581638  0.92
1984 Jennings LK, Dockter ME, Walker WS. Cytofluorimetric analysis of platelet membrane glycoproteins IIb and III using monoclonal antibodies Federation Proceedings. 43.  0.92
1983 Phillips DR, Fujimura K, Jennings LK. Calcium regulation of glycoproteins IIb and IIIa in human platelet membranes Annals of the New York Academy of Sciences. 166-175. PMID 6329055  0.92
1982 Phillips DR, Jennings LK, Berndt MC. Studies of inherited bleeding disorders to identify platelet membrane glycoproteins involved in adhesion and aggregation Progress in Clinical and Biological Research. 97: 151-163. PMID 6296877  0.92
1982 Jennings LK, Phillips DR. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex Journal of Biological Chemistry. 257: 10458-10466. PMID 6213621  0.92
1981 Jennings LK, Fox JEB, Edwards HH, Phillips DR. Changes in the cytoskeletal structure of human platelets following thrombin activation Journal of Biological Chemistry. 256: 6927-6932. PMID 6894599  0.92
1980 Phillips DR, Jennings LK, Edwards HH. Identification of membrane proteins mediating the interaction of human platelets Journal of Cell Biology. 86: 77-86. PMID 6893455  0.92
1980 Phillips DR, Jennings LK, Prasanna HR. Ca2+-mediated association of glycoprotein G (thrombin sensitive protein, thrombospondin) with human platelets Journal of Biological Chemistry. 255: 11629-11632. PMID 6777381  0.92
Show low-probability matches.